Biotage AB (publ)

OM:BIOT Stock Report

Market Cap: SEK 14.8b

Biotage Management

Management criteria checks 3/4

Biotage's CEO is Torben Jorgensen, appointed in Jan 2024, has a tenure of less than a year. directly owns 0.4% of the company’s shares, worth SEK59.33M. The average tenure of the management team and the board of directors is 3.5 years and 2.6 years respectively.

Key information

Torben Jorgensen

Chief executive officer

SEK 857.0k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.4%
Management average tenure3.5yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Jul 19
Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Jun 08
Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

May 21
Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Apr 28
Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Apr 17
Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Apr 08
Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Apr 03
Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Mar 04
Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Feb 22
Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Feb 21
Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 18
Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Feb 08
Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

Jan 07
Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Dec 08
At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Oct 27
Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Jul 12
Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Jun 08
An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

May 24
Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 05
Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Mar 12
These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Feb 21
Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?

Jan 06
Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?

Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly

Dec 03
Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly

Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?

Oct 27
Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?

Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)

Oct 07
Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)

Biotage (STO:BIOT) Could Easily Take On More Debt

Sep 03
Biotage (STO:BIOT) Could Easily Take On More Debt

Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?

Jul 10
Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?

A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)

Jun 25
A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)

Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?

May 28
Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 23
Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Biotage (STO:BIOT) Is Paying Out A Larger Dividend Than Last Year

Mar 29
Biotage (STO:BIOT) Is Paying Out A Larger Dividend Than Last Year

Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Mar 14
Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Is It Time To Consider Buying Biotage AB (publ) (STO:BIOT)?

Feb 28
Is It Time To Consider Buying Biotage AB (publ) (STO:BIOT)?

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Feb 13
Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

CEO Compensation Analysis

How has Torben Jorgensen's remuneration changed compared to Biotage's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

SEK 251m

Mar 31 2024n/an/a

SEK 236m

Dec 31 2023SEK 857kn/a

SEK 246m

Sep 30 2023n/an/a

SEK 189m

Jun 30 2023n/an/a

SEK 216m

Mar 31 2023n/an/a

SEK 240m

Dec 31 2022SEK 817kn/a

SEK 268m

Sep 30 2022n/an/a

SEK 240m

Jun 30 2022n/an/a

SEK 228m

Mar 31 2022n/an/a

SEK 216m

Dec 31 2021SEK 732kn/a

SEK 205m

Sep 30 2021n/an/a

SEK 203m

Jun 30 2021n/an/a

SEK 187m

Mar 31 2021n/an/a

SEK 174m

Dec 31 2020SEK 2mSEK 1m

SEK 175m

Sep 30 2020n/an/a

SEK 149m

Jun 30 2020n/an/a

SEK 179m

Mar 31 2020n/an/a

SEK 201m

Dec 31 2019SEK 7mSEK 3m

SEK 187m

Sep 30 2019n/an/a

SEK 196m

Jun 30 2019n/an/a

SEK 173m

Mar 31 2019n/an/a

SEK 170m

Dec 31 2018SEK 7mSEK 3m

SEK 168m

Sep 30 2018n/an/a

SEK 175m

Jun 30 2018n/an/a

SEK 162m

Mar 31 2018n/an/a

SEK 148m

Dec 31 2017SEK 6mSEK 3m

SEK 139m

Compensation vs Market: Torben's total compensation ($USD80.22K) is below average for companies of similar size in the Swedish market ($USD745.14K).

Compensation vs Earnings: Torben's compensation has been consistent with company performance over the past year.

CEO

Torben Jorgensen (72 yo)

less than a year

Tenure

SEK 857,000

Compensation

Mr. Torben Jorgensen, B.Sc. serves as President at Biotage AB form January 04, 2024 and serves as its as CEO since 2024 and served as its as Interim CEO since January 04, 2024 until 2024 and served as its...

Leadership Team

NamePositionTenureCompensationOwnership
Torben Jorgensen
CEO, President & Directorless than a yearSEK 857.00k0.40%
SEK 59.3m
Andrew Kellett
Chief Financial Officerless than a yearno datano data
Anders Wikstrom
Executive Vice President of Operations14.2yrsno data0.0064%
SEK 953.3k
Raffaella Bombarda
EVP of Global Marketingno datano datano data
Petra Duprez
Chief Human Resources & Sustainability Officerno datano data0.019%
SEK 2.8m
Scott Carr
President of Americas & Chief/Head of Americasno datano data0.0064%
SEK 953.3k
Jonas Stahlberg
Chief Auditorno datano datano data
Olof Nord
Executive Vice President of Business Developmentno datano data0.025%
SEK 3.7m
Andreas Juhlin
President of International - EMEA and APAC4.1yrsno data0.0064%
SEK 953.3k
Magnus Nordstedt
Executive Vice President of IT & Digitalizationno datano data0.0059%
SEK 868.8k
Lisa Egelrud
Executive Vice President of Quality Assurance & Regulatory Affairs3.5yrsno datano data
Maryam Poorafshar
Executive Vice President R&Dno datano datano data

3.5yrs

Average Tenure

52.5yo

Average Age

Experienced Management: BIOT's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Torben Jorgensen
CEO, President & Director4.7yrsSEK 857.00k0.40%
SEK 59.3m
Kieran Murphy
Chairman1.3yrsSEK 227.00kno data
Peter von Ehrenheim
Director11.3yrsSEK 407.00k0.020%
SEK 3.0m
Asa Hedin
Director4.7yrsSEK 337.00kno data
Mark Bradley
Director5.3yrsSEK 307.00kno data
Kugan Sathiyanandarajah
Director1.3yrsno datano data
Dan Menasco
Employee Representative Director2.6yrsno datano data
Karen Soerensen
Director2.3yrsSEK 357.00kno data
Par Lundgren
Employee Representative Directorno datano datano data
Philip Lamberstam
Employee Representative Directorless than a yearno datano data

2.6yrs

Average Tenure

61.5yo

Average Age

Experienced Board: BIOT's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.